Search
for
Sort by
Research 151–180 of 274
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Industry updates in advanced therapy medicinal products and regenerative medicine – March 2026
- Post-finasteride syndrome – does it really exist?
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
- Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
- Finasteride and Suicide: A Postmarketing Case Series
- Supplementary Material for: Finasteride and Suicide: A Postmarketing Case Series
- Pilot Clinical Evaluation of a Hyaluronic Acid– and Hydrogen Peroxide–Based Gel in the Management of Folliculitis: An Open-Label, Post-Marketing Study
- Finasteride and androgenic alopecia; from therapeutic options to medical implications
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review
- Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry—The European and North America Regulation Challenges
- Serum Levels of VWF, t-PA, TNF-α, and ICAM-1 in Patients Receiving Hemocoagulase Combined with Platelet-Rich Plasma during Total Hip Replacement
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Wound Healing Impairment in Type 2 Diabetes Model of Leptin-Deficient Mice—A Mechanistic Systematic Review
- Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
- Rivaroxaban-induced hair loss
- Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia
- Finasteride
- Revisiting dandruff
- Aspect-Level Drug Reviews Sentiment Analysis Based on Double BiGRU and Knowledge Transfer
- Topical absorption and systemic toxicity
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
- Primary cicatricial alopecia
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- Adverse Cutaneous Reactions to Mood Stabilizers
- 5α-Reductase inhibitors in androgenetic alopecia
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- Nonsurgical Therapy for Hair Loss